ClinicalTrials.gg
CompletedNCT04666259AIM4CMLUpdated Oct 16, 2025Results posted

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

A Phase 3 interventional study of ABL001 in Chronic Myelogenous Leukemia - Chronic Phase, sponsored by Novartis Pharmaceuticals. Completed at 26 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis — 2 open to participants now, 3 under way, none of them phase 3. Leukemia, Myeloid, Chronic-Phase · Novartis.

Started
2021
the only one that year
Phase 3
3 of 14
none open now
Registered
9th of 14
by date

Among the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis, this one is the only one that started in 2021, is one of 3 in phase 3, and was the 9th registered.

Leukemia, Myeloid, Chronic-Phase

439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.

Browse Leukemia, Myeloid, Chronic-Phase studies →

Open to participants now

2 of the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 20 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis, or all of them as a file.
02

Study summary

This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior TKI

Read the detailed description

This trial consisted of three periods: screening and baseline for up to 21 days, active treatment for up to 72 weeks and a safety follow up period for 30 days.

One hundred and fifteen (115) patients with chronic myeloid leukemia in chronic phase (CML-CP) without T315I mutation who have had at least 2 prior Tyrosine Kinase Inhibitors (TKIs) and CML-CP with the T315I mutation with at least 1 prior TKI were planned for this study, however the study was finally completed with 56 participants due to enrollment issues.

Informed consent was obtained before any procedures were performed for the study including eligibility assessments. The results of the real time quantitative polymerase chain reaction (RQ-PCR) must be available prior to randomization and first dose of study treatment.

Patients with CML-CP without T315I mutation were randomly assigned to either cohort A or B. Patients with the T315I mutation were enrolled in cohort C. During treatment period asciminib was taken orally: Cohort A was administered 40 mg twice a day, Cohort B was administered 80 mg once a day and Cohort C was administered 200 mg twice a day. The patients were treated up to end of study treatment period defined as up to 72 weeks after the last patient receives the first dose. Patients may have been discontinued from treatment with the study drug at any time due to unacceptable toxicity, disease progression and/or at the discretion of the investigator or the patient.

03

Conditions studied

  • Chronic Myelogenous Leukemia - Chronic Phase

Keywords

  • CML
  • T315I mutation
  • CP
  • Asciminib,
  • BCR-ABL,
  • ABL001,
  • CML-AP,
  • ELN
  • MMR
  • Molecular Response
  • MR4.5
  • MR4
  • RQ-PCR
  • AIM4CML,
  • tyrosine Kinase Inhibitor
  • TKI
  • adult
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants eligible for inclusion in this study must meet all of the following criteria:

  1. Written must be obtained and signed prior to participation in the study
  2. Male or female patients with a diagnosis of CML-CP ≥ 18 years of age
  3. Patients must meet all of the following laboratory values at the screening visit:

    • \< 15% blasts in peripheral blood and/or bone marrow
    • \< 30% blasts plus promyelocytes in peripheral blood and/or bone marrow
    • \< 20% basophils in the peripheral blood
    • ≥ 50 x 109/L (≥ 50,000/ mm3)
    • Transient prior therapy related thrombocytopenia (\< 50,000/mm3 for ≤ 30 days prior to screening) is acceptable
    • No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly
  4. Mutation Analysis testing performed 6 months before study entry
  5. Prior treatment with a minimum of:

    • 2 prior ATP-site TKIs (i.e. imatinib, nilotinib, bosutinib, dasatinib or ponatinib) in case of absence of T315I mutation
    • 1 prior ATP site TKI (i.e. imatinib, nilotinib, bosutinib, dasatinib or ponatinib) in case of presence of T315I mutation
  6. Failure (adapted from the 2020 ELN Recommendations) or intolerance to the most recent TKI therapy at the time of screening

    • Failure for CML-CP patients (CP at the time of initiation of last therapy) is defined as meeting at least one of the following criteria.
    • Three months after the initiation of therapy: >10% BCR-ABL1 on International Scale (IS) if confirmed within 1-3 months
    • Six months after the initiation of therapy: BCR-ABL1 ratio > 10% IS
    • Twelve months after initiation of therapy: BCR-ABL1 ratio > 1% IS
    • At any time after the initiation of therapy, loss of CHR, MR2
    • At any time after the initiation of therapy, the development of new BCR-ABL1 mutations which potentially cause resistance to current treatment
    • At any time 12 months after the initiation of therapy, BCR-ABL1 ratio ≥ 1% IS or loss of MMR
    • At any time after the initiation of therapy, new clonal chromosome abnormalities in Ph+ cells: CCA/Ph+
    • Intolerance is defined as:
    • Non-hematologic intolerance: Patients with grade 3 or 4 toxicity while on therapy, or with persistent grade 2 toxicity, unresponsive to optimal management, including dose adjustments (unless dose reduction is not considered in the best interest of the patient if response is already suboptimal)
    • Hematologic intolerance: Patients with grade 3 or 4 toxicity ( [ANC] or platelets) while on therapy that is recurrent after dose reduction to the lowest doses recommended by manufacturer
  7. (ECOG) performance status (PS) of 0, 1, or 2
  8. Evidence of typical BCR-ABL1 transcript [e14a2 and/or e13a2] at the time of screening which are amenable to standardized RQ-PCR quantification.
  9. Adequate end organ function, within 12 days before the first dose of asciminib treatment. Patients with mild to moderate renal and hepatic impairment are eligible if:

    • Total ≤ 3.0 x without /ALT increase
    • Aspartate transaminase (AST) ≤ 5.0 x ULN
    • Alanine transaminase (ALT) ≤ 5.0 x ULN
    • Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value should be considered not and not associated with risk factors for acute pancreatitis
    • Alkaline phosphatase ≤ 2.5 x ULN
    • ≥ 30 mL/min as calculated using Cockcroft-Gault formula
  10. Patients must avoid consumption of grapefruit, Seville oranges or products containing the juice of each during the entire study and preferably 7 days before the first dose of study medications, due to potential interaction with the study medications. Orange juice is allowed.
  11. Treatment with medications that meet one of the following criteria is allowed if used with caution at least one week prior to the start of treatment with study treatment:

    • Moderate or strong inducers of CYP3A
    • Moderate or strong inhibitors of CYP3A
  12. Patients must have the following electrolyte values (as per central laboratory tests) within normal limits or corrected to be within normal limits with supplements prior to first dose of study medication:

    • Potassium (potassium increase of up to 6.0 mmol/L is acceptable at study entry if associated with creatinine clearance within normal limits)
    • Total calcium (corrected for serum albumin); (calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable at study entry if associated with creatinine clearance within normal limits)
    • Magnesium, with the exception of magnesium increase > ULN - 3.0 mg/dL; > ULN - 1.23 mmol/L associated with creatinine clearance (calculated using Cockcroft-Gault formula) within normal limits.

Exclusion criteria

Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

  1. Known second chronic phase of CML after previous progression to AP/BC
  2. Previous treatment with a hematopoietic stem-cell transplantation
  3. Cardiac or cardiac repolarization abnormality, including any of the following:

    • History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG)
    • cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block)
    • at screening ≥450 msec (male patients), ≥460 msec (female patients)
    • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
    • Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
    • Concomitant medication(s) with a "Known risk of Torsades de Pointes" per wwwcrediblemeds.org/ that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.
    • Inability to determine the QTcF interval
  4. Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pulmonary hypertension)
  5. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  6. Known presence of significant congenital or acquired bleeding disorder unrelated to cancer
  7. History of other active within 3 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively
  8. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
  9. Previous treatment with or known/ suspected to asciminib or any of its .
  10. Participation in a prior study within 30 days prior to randomization or within 5 half-lives of the investigational product, whichever is longer
  11. Pregnant or nursing (lactating) women
  12. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of .

    Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy (with or without hysterectomy) total hysterectomy or bilateral tubal ligation at least six weeks before taking study treatment). In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.
    • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.
    • In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
    • Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks before taking study medication. In the case of oophorectomy alone, women are considered post-menopausal and not of child bearing potential only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
  13. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 3 days after stopping study (only for patients treated with asciminib). A condom is required for all sexually active male participants on asciminib treatment to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, these male participants must not donate sperm for the time period specified above.
  14. If a patient is presenting with symptoms suggestive of possible COVID-19 infection, we advise ruling it out by appropriate testing recommended by health authorities.

    • Nucleic acid amplification tests for viral RNA (polymerase chain reaction), in order to measure current infection with SARS-CoV-2
    • Antigen tests for rapid detection of SARS-CoV-2
    • Antibody (serology) tests to detect the presence of antibodies to SARS-CoV-2
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Cohort A

    40 mg asciminib orally twice daily (BID)

    Drug: ABL001

  • Experimental
    Cohort B

    80 mg asciminib orally once daily (QD)

    Drug: ABL001

  • Experimental
    Cohort C

    200 mg asciminib orally twice daily (BID)

    Drug: ABL001

Interventions

  • DrugABL001

    Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks

    Adverse events (AEs) and serious adverse events (SAEs) are summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) are reported as adverse events and or serious adverse events as determined by the investigator.

    Time frame: Baseline to up to 24 Weeks

Secondary outcomes

  1. Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A, B and C by Week 48

    Adverse events (AEs) and serious adverse events (SAEs) were summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) were reported as adverse events and or serious adverse events as determined by the investigator.

    Time frame: Baseline up to 48 weeks

  2. Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A, B and C by Week 72

    Adverse events (AEs) and serious adverse events (SAEs) were summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) were reported as adverse events and or serious adverse events as determined by the investigator.

    Time frame: Baseline up to 72 weeks

  3. Percentage of Patients Achieving Complete Hematologic Response (CHR) for Cohorts A, B and C

    A complete hematologic response (CHR) is defined as all of the following present for ≥ 4 weeks: * White blood cell count (WBC) \<10 x 10\^9/L * Platelet count \<450 x 10\^9/L * Basophils \<5%, * No blasts and promyelocytes in peripheral blood * Myelocytes + metamyelocytes \< 5% in peripheral blood * No evidence of extramedullary disease, including spleen and liver The estimated cumulative incidence rates were presented.

    Time frame: Baseline to 12, 24, 48, 72 weeks

  4. Percentage of Patients Achieving Major Molecular Response (MMR) for Cohorts A, B and C

    The rate of major molecular response (MMR) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 3 log reduction of BCR-ABL (transcript from standardized baseline or ≤0.1% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.

    Time frame: Baseline up to 12, 24, 48, 72 weeks

  5. Percentage of Patients Achieving Molecular Response (MR2) for Cohorts A, B and C

    The rate of molecular response (MR2) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 2 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 1% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.

    Time frame: Baseline up to 12, 24, 48, 72 weeks

  6. Percentage of Patients Achieving Molecular Response 4 (MR4) for Cohorts A, B and C

    The rate of molecular response (MR4) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 4 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 0.01% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.

    Time frame: Baseline up to 12, 24, 48, 72 weeks

  7. Percentage of Patients Achieving Molecular Response 4.5 (MR4.5) for Cohorts A, B and C

    The rate of molecular response (MR4.5) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 4.5 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 0.0032% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.

    Time frame: Baseline up to 12, 24, 48, 72 weeks

  8. Time to Achieve CHR, MR2, MMR, MR4, MR4.5 for Cohorts A, B and C

    Time to achieving a response level is defined as the time from the date of the first dose of study medication to the first documented achievement of each defined response level. Time to achieve a specific response level was analyzed using the Kaplan-Meier Product-Limit method. Patients who are known to be without achieving that response level were censored at the last adequate assessment.

    Time frame: Baseline up to 72 weeks

  9. Duration of CHR, MR2, MMR, MR4 and MR4.5 for Cohorts A, B and C

    Duration of Response (DOR) is the time from the date of the first documented molecular response level to the date of first documented loss of the response level or death due to any cause, whichever occurs first. DOR for each response level was analyzed using the Kaplan-Meier Product-Limit method. Participants continuing without that event were censored at the date of their last adequate response assessment.

    Time frame: Baseline up 72 weeks

  10. Progression Free Survival (PFS) for Cohorts A, B and C

    Progression Free Survival (PFS) is defined as time from the first dose of study medication to disease progression to accelerated phase/blast crisis (AP/BC) or death due to any cause, whichever occurs first. PFS was analyzed using the Kaplan-Meier Product-Limit method. Subjects who did not progress were censored at the last adequate assessment.

    Time frame: Baseline up to 72 weeks

  11. Overall Survival Overall Survival (OS) for Cohorts A, B and C

    Overall Survival (OS) is defined as the time from the first dose of study medication to death due to any cause during study. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive. OS was analyzed using the Kaplan-Meier Product-Limit method

    Time frame: Baseline up to 72 weeks

07

Results

Posted Jul 12, 2024

Participant flow

Treatment Phase
Participant flow — Treatment Phase
MilestoneCohort ACohort BCohort C
Started26273
Treated25273
Completed12200
Not completed1473
Withdrew: Physician decision933
Withdrew: Adverse event310
Withdrew: Subject decision120
Withdrew: Progressive disease010
Withdrew: Enrolled but not treated and discontinued100
Safety Follow-up Phase
Participant flow — Safety Follow-up Phase
MilestoneCohort ACohort BCohort C
Started23243
Completed20233
Not completed310
Withdrew: Physician decision200
Withdrew: Subject decision100
Withdrew: Death010

Outcome measures

PrimaryNumber of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks

Adverse events (AEs) and serious adverse events (SAEs) are summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) are reported as adverse events and or serious adverse events as determined by the investigator.

Time frame:
Baseline to up to 24 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks
ParticipantsCohort ACohort B
Adverse Events (AEs)2326
Serious Adverse Events (SAEs)13
Fatal SAEs01
AEs leading to treatment discontinuation21
AEs leading to dose adjustment/interruption79
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events for Cohorts A, B and C by Week 48

Adverse events (AEs) and serious adverse events (SAEs) were summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) were reported as adverse events and or serious adverse events as determined by the investigator.

Time frame:
Baseline up to 48 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A, B and C by Week 48
ParticipantsCohort ACohort BCohort C
Adverse Events (AEs)24263
Serious Adverse Events (SAEs)231
Fatal SAEs010
AEs leading to treatment discontinuation310
AEs leading to dose adjustment/interruption7102
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events for Cohorts A, B and C by Week 72

Adverse events (AEs) and serious adverse events (SAEs) were summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) were reported as adverse events and or serious adverse events as determined by the investigator.

Time frame:
Baseline up to 72 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A, B and C by Week 72
ParticipantsCohort ACohort BCohort C
Adverse Events (AEs)24263
Serious Adverse Events (SAEs)441
Fatal SAEs010
AEs leading to treatment discontinuation310
AEs leading to dose adjustment/interruption8112
SecondaryPercentage of Patients Achieving Complete Hematologic Response (CHR) for Cohorts A, B and C

A complete hematologic response (CHR) is defined as all of the following present for ≥ 4 weeks: * White blood cell count (WBC) \<10 x 10\^9/L * Platelet count \<450 x 10\^9/L * Basophils \<5%, * No blasts and promyelocytes in peripheral blood * Myelocytes + metamyelocytes \< 5% in peripheral blood * No evidence of extramedullary disease, including spleen and liver The estimated cumulative incidence rates were presented.

Time frame:
Baseline to 12, 24, 48, 72 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients Achieving Complete Hematologic Response (CHR) for Cohorts A, B and C
Percentage of participantsCohort ACohort BCohort C
12 weeks76.9 (56.4 to 91.0)92.6 (75.7 to 99.1)100 (29.2 to 100)
24 weeks76.9 (56.4 to 91.0)92.6 (75.7 to 99.1)100 (29.2 to 100)
48 weeks76.9 (56.4 to 91.0)92.6 (75.7 to 99.1)100 (29.2 to 100)
72 weeks76.9 (56.4 to 91.0)92.6 (75.7 to 99.1)100 (29.2 to 100)
SecondaryPercentage of Patients Achieving Major Molecular Response (MMR) for Cohorts A, B and C

The rate of major molecular response (MMR) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 3 log reduction of BCR-ABL (transcript from standardized baseline or ≤0.1% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.

Time frame:
Baseline up to 12, 24, 48, 72 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients Achieving Major Molecular Response (MMR) for Cohorts A, B and C
Percentage of participantsCohort ACohort BCohort C
12 weeks38.5 (20.2 to 59.4)44.4 (25.5 to 64.7)0 (0.0 to 70.8)
24 weeks42.3 (23.4 to 63.1)63.0 (42.4 to 80.6)0 (0.0 to 70.8)
48 weeks46.2 (26.6 to 66.6)70.4 (49.8 to 86.3)0 (0.0 to 70.8)
72 weeks50.0 (29.9 to 70.1)70.4 (49.8 to 86.3)0 (0.0 to 70.8)
SecondaryPercentage of Patients Achieving Molecular Response (MR2) for Cohorts A, B and C

The rate of molecular response (MR2) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 2 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 1% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.

Time frame:
Baseline up to 12, 24, 48, 72 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients Achieving Molecular Response (MR2) for Cohorts A, B and C
Percentage of participantsCohort ACohort BCohort C
12 weeks53.8 (33.4 to 73.4)70.4 (49.8 to 86.3)0 (0.0 to 70.8)
24 weeks57.7 (36.9 to 76.7)85.2 (66.3 to 95.8)0 (0.0 to 70.8)
48 weeks61.5 (40.6 to 79.8)85.2 (66.3 to 95.8)0 (0.0 to 70.8)
72 weeks61.5 (10.6 to 79.8)85.2 (66.3 to 95.8)0 (0.0 to 70.8)
SecondaryPercentage of Patients Achieving Molecular Response 4 (MR4) for Cohorts A, B and C

The rate of molecular response (MR4) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 4 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 0.01% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.

Time frame:
Baseline up to 12, 24, 48, 72 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients Achieving Molecular Response 4 (MR4) for Cohorts A, B and C
Percentage of participantsCohort ACohort BCohort C
12 weeks30.8 (14.3 to 51.8)18.5 (6.3 to 38.1)0 (0.0 to 70.8)
24 weeks30.8 (14.3 to 51.8)29.6 (13.8 to 50.2)0 (0.0 to 70.8)
48 weeks38.5 (20.2 to 59.4)44.4 (25.5 to 64.7)0 (0.0 to 70.8)
72 weeks38.5 (20.2 to 59.4)48.1 (28.7 to 68.1)0 (0.0 to 70.8)
SecondaryPercentage of Patients Achieving Molecular Response 4.5 (MR4.5) for Cohorts A, B and C

The rate of molecular response (MR4.5) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 4.5 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 0.0032% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.

Time frame:
Baseline up to 12, 24, 48, 72 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients Achieving Molecular Response 4.5 (MR4.5) for Cohorts A, B and C
Percentage of participantsCohort ACohort BCohort C
12 weeks23.1 (9.0 to 43.7)11.1 (2.4 to 29.2)0 (0.0 to 70.8)
24 weeks26.9 (11.6 to 47.8)18.5 (6.3 to 38.1)0 (0.0 to 70.8)
48 weeks30.8 (14.3 to 51.8)25.9 (11.1 to 46.3)0 (0.0 to 70.8)
72 weeks30.8 (14.3 to 51.8)29.6 (13.8 to 50.2)0 (0.0 to 70.8)
SecondaryTime to Achieve CHR, MR2, MMR, MR4, MR4.5 for Cohorts A, B and C

Time to achieving a response level is defined as the time from the date of the first dose of study medication to the first documented achievement of each defined response level. Time to achieve a specific response level was analyzed using the Kaplan-Meier Product-Limit method. Patients who are known to be without achieving that response level were censored at the last adequate assessment.

Time frame:
Baseline up to 72 weeks
Reported as:
Median · weeks
Time to Achieve CHR, MR2, MMR, MR4, MR4.5 for Cohorts A, B and C
weeksCohort ACohort BCohort C
CHR11.1 (11.1 to 12.00)11.9 (11.1 to 12.1)11.1 (10.9 to NA)
MMR24.0 (4.1 to NA)22.9 (11.1 to 28.3)NA (NA to NA)
MR28.3 (4.0 to 47.0)4.3 (3.9 to 11.6)NA (NA to NA)
MR436.1 (11.1 to NA)58.6 (23.1 to NA)NA (NA to NA)
MR4.5NA (23.1 to NA)NA (48.1 to NA)NA (NA to NA)
SecondaryDuration of CHR, MR2, MMR, MR4 and MR4.5 for Cohorts A, B and C

Duration of Response (DOR) is the time from the date of the first documented molecular response level to the date of first documented loss of the response level or death due to any cause, whichever occurs first. DOR for each response level was analyzed using the Kaplan-Meier Product-Limit method. Participants continuing without that event were censored at the date of their last adequate response assessment.

Time frame:
Baseline up 72 weeks
Reported as:
Median · weeks
Duration of CHR, MR2, MMR, MR4 and MR4.5 for Cohorts A, B and C
weeksCohort ACohort BCohort C
CHRNA (NA to NA)NA (NA to NA)NA (NA to NA)
MMRNA (NA to NA)NA (NA to NA)—
MR2NA (NA to NA)NA (NA to NA)—
MR 4NA (NA to NA)NA (2.9 to NA)—
MR 4.5NA (NA to NA)NA (NA to NA)—
SecondaryProgression Free Survival (PFS) for Cohorts A, B and C

Progression Free Survival (PFS) is defined as time from the first dose of study medication to disease progression to accelerated phase/blast crisis (AP/BC) or death due to any cause, whichever occurs first. PFS was analyzed using the Kaplan-Meier Product-Limit method. Subjects who did not progress were censored at the last adequate assessment.

Time frame:
Baseline up to 72 weeks
Reported as:
Median · weeks
Progression Free Survival (PFS) for Cohorts A, B and C
weeksCohort ACohort BCohort C
Progression Free Survival (PFS) for Cohorts A, B and CNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryOverall Survival Overall Survival (OS) for Cohorts A, B and C

Overall Survival (OS) is defined as the time from the first dose of study medication to death due to any cause during study. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive. OS was analyzed using the Kaplan-Meier Product-Limit method

Time frame:
Baseline up to 72 weeks
Reported as:
Median · weeks
Overall Survival Overall Survival (OS) for Cohorts A, B and C
weeksCohort ACohort BCohort C
Overall Survival Overall Survival (OS) for Cohorts A, B and CNA (NA to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over From Baseline to 30 days after last treatment (up to a maximum of approximately 85 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A0/25 (0%)4/25 (16%)24/25 (96%)
Cohort B2/27 (7.4%)4/27 (14.8%)26/27 (96.3%)
Cohort C0/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCohort ACohort BCohort C
MalaiseGeneral disorders0/250/271/3
COVID-19 pneumoniaInfections and infestations1/250/270/3
Pelvic infectionInfections and infestations1/250/270/3
Meniscus injuryInjury, poisoning and procedural complications1/250/270/3
ArthralgiaMusculoskeletal and connective tissue disorders1/250/270/3
Neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/250/270/3
Brain stem infarctionNervous system disorders1/250/270/3
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/250/270/3
Acute coronary syndromeCardiac disorders0/251/270/3
Myocardial infarctionCardiac disorders0/251/270/3
Most frequent other events
Showing 10 of 71
Most frequent other events
EventCohort ACohort BCohort C
NauseaGastrointestinal disorders3/258/272/3
FatigueGeneral disorders10/259/271/3
ArthralgiaMusculoskeletal and connective tissue disorders6/2510/271/3
HeadacheNervous system disorders9/257/270/3
AnaemiaBlood and lymphatic system disorders0/252/271/3
ThrombocytopeniaBlood and lymphatic system disorders2/252/271/3
Abdominal distensionGastrointestinal disorders1/250/271/3
VomitingGastrointestinal disorders3/255/271/3
Oedema peripheralGeneral disorders2/253/271/3
Viral diarrhoeaInfections and infestations0/250/271/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort ACohort BCohort CTotal
<=18 years0000
Between 18 and 65 years1719339
>=65 years98017
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort BCohort CTotal
Female1614030
Male1013326
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ACohort BCohort CTotal
American Indian or Alaska Native0000
Asian0202
Native Hawaiian or Other Pacific Islander0000
Black or African American4217
White2122144
More than one race0000
Unknown or Not Reported1113
08

Study locations

26 sites
  • Alaska Oncology and Hematology
    Anchorage, Alaska 99508, United States
  • Arizona Oncology Associates
    Phoenix, Arizona 85016, United States
  • Cancer Treatment Centers of America
    Phoenix, Arizona 85027, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Lundquist Inst BioMed at Harbor
    Torrance, California 90509-2910, United States
  • Rocky Mountain Cancer Centers
    Boulder, Colorado 80304, United States
  • Memorial Cancer Institute
    Hollywood, Florida 33021, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Florida Cancer Specialists-North
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists East
    Stuart, Florida 34994, United States
  • Florida Cancer Specialists Pan
    Tallahassee, Florida 32308, United States
  • Indiana Blood and Marrow Institute
    Beech Grove, Indiana 46107, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Uni of Massachusetts Medical Center
    Worcester, Massachusetts 01655, United States
  • Michigan Med University of Michigan
    Ann Arbor, Michigan 48109 5271, United States
  • Siteman Cancer Center
    St Louis, Missouri 63110, United States
  • Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Uni of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45242, United States
  • Northwest Cancer Specialists
    Portland, Oregon 97210, United States
  • Texas Oncology
    Dallas, Texas 75251, United States
  • Texas Oncology P A
    Fort Worth, Texas 76104, United States
  • Univ of TX MD Anderson Cancer Cntr
    Houston, Texas 77030, United States
  • Texas Oncology Northeast Texas
    Tyler, Texas 75702, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jun 2023, 24 months.

Results were first posted in Jul 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2020
First posted
Dec 14, 2020
StartActual
May 25, 2021
Primary completionActual
Jun 20, 2023
CompletionActual
Jun 26, 2024
Results first posted
Jul 12, 2024
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04666259
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
May 25, 2021
Primary completion
Jun 20, 2023
Completion
Jun 26, 2024
Results posted
Jul 12, 2024
Last update
Oct 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion